Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Senzime

4.51 SEK

+0.11 %

Less than 1K followers

SEZI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.11 %
-9.90 %
-16.57 %
-10.44 %
-26.75 %
-19.55 %
-38.29 %
-80.14 %
-24.09 %

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Read more
Market cap
708.25M SEK
Turnover
296.6K SEK
Revenue
104.02M
EBIT %
-117.84 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
22/4
2026

Interim report Q1'26

19/5
2026

General meeting '26

16/7
2026

Interim report Q2'26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Press release2/19/2026, 8:35 AM

Redeye: Senzime (Q4 Review): Solid report and a positive 2026 outlook

Senzime
Press release2/19/2026, 8:00 AM

Senzime lanserar TetraCom connectivity platform för universell integration av anestesidata

Senzime
Press release2/19/2026, 8:00 AM

Senzime launches TetraCom connectivity platform enabling universal transmission of anesthesia data

Senzime

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2/18/2026, 10:30 AM

Redeye: Senzime (Q4 Initial take): Sales spot on to our estimate

Senzime
Regulatory press release2/18/2026, 7:30 AM

Senzime Q4 2025: Accelererad tillväxt och fortsatt tydlig väg mot lönsamhet

Senzime
Regulatory press release2/18/2026, 7:30 AM

Senzime Q4 2025: Accelerated growth and continued clear path to profitability

Senzime
Regulatory press release2/18/2026, 7:30 AM

Senzime säkrar kreditfacilitet om totalt 50 MSEK

Senzime
Regulatory press release2/18/2026, 7:30 AM

Senzime secures credit line facility of 50 MSEK

Senzime
Press release2/11/2026, 12:45 PM

Inbjudan till presentationer av Senzimes bokslutskommuniké för 2025

Senzime
Press release2/11/2026, 12:45 PM

Invitation to presentations of Senzime’s Q4 and Year-End Report 2025

Senzime
Press release1/21/2026, 8:30 AM

Senzime säkrar större avtal med ledande Ivy League-sjukhus i USA

Senzime
Press release1/21/2026, 8:30 AM

Senzime secures major Ivy League US hospital system contract

Senzime
Press release12/17/2025, 7:45 AM

Senzimes Next-generation TetraGraph-system erhåller regulatoriskt godkännande i Japan

Senzime
Press release12/17/2025, 7:45 AM

Senzime’s Next-generation TetraGraph system receives regulatory approval in Japan

Senzime
Press release12/10/2025, 12:30 PM

Senzime unveils the next set of innovations in neuromuscular monitoring with the launch of EMGINE Sirius

Senzime
Press release12/10/2025, 12:30 PM

Senzime lanserar nya innovationer inom neuromuskulär övervakning med EMGINE Sirius

Senzime
Press release12/9/2025, 8:00 AM

Senzime säkrar större order på TetraGraph-system från ledande NHS-sjukhussystem i Storbritannien

Senzime
Press release12/9/2025, 8:00 AM

Senzime secures major TetraGraph order from leading UK NHS hospital system

Senzime
Press release11/19/2025, 7:09 AM

BioStock: Video från Senzimes presentation vid BioStock Life Science Summit 2025

Senzime
Press release11/19/2025, 7:09 AM

BioStock: Video from Senzime's presentation at BioStock Life Science Summit 2025

Senzime
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.